STOCK TITAN

Daniel Kaufman holds 1.878M Harrow shares (HROW) — 5.04% reported

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Harrow, Inc. Schedule 13G reports that Daniel Kaufman beneficially owns 1,878,000 shares of Common Stock, representing 5.04% as of 03/10/2026.

The filing lists Kaufman’s sole voting and dispositive power over the 1,878,000 shares. The address and CUSIP are provided in the disclosure.

Positive

  • None.

Negative

  • None.

Insights

Beneficial owner files passive Schedule 13G showing a >5% stake.

Daniel Kaufman is reported as beneficial owner of 1,878,000 shares with sole voting and dispositive power, representing 5.04% as of 03/10/2026.

Schedule 13G is typically passive reporting; the filing does not state changes to voting agreements or plans. Subsequent filings would show any active purchases or sales.

Holding size is visible; trading implications depend on future disclosures.

The disclosure quantifies a 5.04% beneficial position (1,878,000 shares) and confirms sole vote/dispositive authority for Kaufman as of 03/10/2026.

Market impact or intent is not stated in this excerpt; any change in holdings would be reported in later filings.






03/10/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G



Daniel Kaufman
Signature:/s/ Daniel Kaufman
Name/Title:Daniel Kaufman, Individual Investor
Date:03/10/2026
Exhibit Information

None

FAQ

What stake does Daniel Kaufman report in Harrow (HROW)?

He reports beneficial ownership of 1,878,000 shares. The filing states this equals 5.04% of Harrow's common stock as of 03/10/2026, with sole voting and dispositive power.

What form was filed to disclose Daniel Kaufman’s holdings in HROW?

A Schedule 13G was filed. The Schedule 13G lists passive beneficial ownership and shows Kaufman’s amount, voting/dispositive powers, address, and the issuer CUSIP (415858109).

Does the Schedule 13G indicate Kaufman plans to buy or sell Harrow shares?

No transaction intent is stated in the excerpt. The filing lists current beneficial ownership of 1,878,000 shares and does not describe purchases, sales, or plans to transact.

What voting and dispositive powers does Kaufman have over the shares?

The filing reports sole voting power of 1,878,000 shares and sole dispositive power of 1,878,000 shares, with no shared powers reported in the Schedule 13G.

Where can investors find identifying details from the filing?

The Schedule 13G includes the issuer address (Nashville, TN), the filer’s address (San Juan, Puerto Rico), and the issuer CUSIP 415858109, all shown in the disclosure.
Harrow Health Inc

NASDAQ:HROWM

View HROWM Stock Overview

HROWM Rankings

HROWM Latest SEC Filings

HROWM Stock Data

Pharmaceutical Preparations
NASHVILLE